MAP2K7 and melanoma: Further downstream mutations in RAF/MEK/ERK cascade (MEK1/2, Erk1/2) are rarely detected in melanoma (4–8%), colorectal cancer (3–4%), or lung adenocarcinoma (0.5–1.5%) [11].